**Te Whatu Ora Health New Zealand**

The National Immunisation Booking System “BookMyVaccine”

*Iterative* Privacy Threshold Analysis\*

8 December 2022

\*For use when a privacy impact assessment has previously been completed.

## Overview

### 1.1 When was the last assessment completed?

|  |
| --- |
| 22 March 2022 |

### 1.2 What was the original project?

|  |
| --- |
| BookMyVaccine (BMV) was developed as part of a suite of technologies by Health NZ to respond to the COVID-19 pandemic. BMV is a booking system that allows New Zealanders to make a booking for a COVID-19 vaccination. The booking system includes the COVID-19 Population Identification and Registration Service (CPIR) and integrations with NHI and the COVID-19 Immunisation Register (CIR). |

### 1.3 What has changed?

|  |
| --- |
| **Background**Mpox, also known as monkeypox, is a viral disease that can be transmitted by close contact with skin lesions (lumps or bumps that can turn into pimples, blisters or sores), body fluids (eg, saliva), respiratory droplets and contaminated materials. mpox is zoonotic, which means it can pass between animals and humans.People who are displaying symptoms, or think they might have been exposed to mpox, are advised to seek medical advice by contacting their nearest sexual health clinic or calling Healthline. BMV has been configured to allow staff at Healthline to book a consultation on behalf of a person at a clinic closest to them.**Configuration**Deployment December 2022Making a booking for a mpox consultation will initially not be available to consumers through the public website, but through a call to Healthline. Healthline staff access the mpox consultations booking flow through [www.bookmyvaccine.co.nz](http://www.bookmyvaccine.co.nz) utilising an ‘access code’ which unlocks the mpox consultation booking flow for the Healthline staff to create a booking on behalf of the consumer.BMV for COVID-19 vaccines will remain unchanged and consumers will not see any difference from the current state.Secondary deployment approximately first quarter 2023It is anticipated that as the programme evolves in the first quarter of 2023 that the booking system will be adjusted to allow consumers to make bookings for mpox consultations using [www.bookmyvaccine.co.nz](http://www.bookmyvaccine.co.nz) directly without the need to call the Healthline. Healthline staff would continue to support consumers to book without an access code. Mpox consultation bookings do not flow through to CIR, as they are not created for a vaccination, rather a consultation. Mpox consultation bookings cannot be searched for using the COVID Immunisation Consumer Support (CICS) tool.Mpox consultation booking personal details will flow through into CPIR as per normal to enable NHI matching. The results of the matching will not be returned to BMV.  |

###

### 1.4 Personal information

Is there a change to the information that is used? [ ]  Yes [x]  No

If **yes**, use the table below to describe the personal information that will be collected used/disclosed/stored; the source of the information; and the purpose of the information.

|  |  |  |
| --- | --- | --- |
| **Type of information** | **Source of Information** | **Purpose of information** |
| Acknowledged Privacy Terms (in the First Phase this will be ‘ticked’ by the Healthline operator after completing the privacy script delivery to the Consumer) | Entered by the Healthline operator on behalf of the consumer | Privacy and authorisation |

## Privacy Assessment

### 2.1 Privacy risks

Has your risk privacy risk assessment impact level changed? [ ]  Yes [x]  No

If **yes**, please rate again:

|  |
| --- |
| **The Privacy Impact for this project is considered to be:**  |
| **Low** – there is little or no personal information involved; the change is minor; the risk of harm eventuating is negligible; or the risks are fully mitigated. |[x]
| **Medium** – there is some personal information involved, but any risks can be satisfactorily mitigated. |[ ]
| **High** – there is sensitive personal information involved and several medium to high risks identified. |[ ]

**4.0 Privacy Analysis and Response (Privacy Team Only)**

### 4.1 IPP risk analysis

|  |  |  |  |
| --- | --- | --- | --- |
| IPP | Risk? Y/N | Description of Risks | Recommendations |
| Collection | N | Collected second hand but with input from the consumer |  |
| Security and Storage | N |  |  |
| Access | N | Locked down so no free flow of information between systems |  |
| Correction | N | Consumers can follow the correction process by contacting hnzPrivacy@health.govt.nz |  |
| Accuracy | N | Information gathered from consumer via Healthline  |  |
| Retention | N | Will sit within the original PIA |  |
| Use | N |  |  |
| Disclosure | N |  |  |
| Unique ID | N | Match process flows through CPIR but no flow back  |  |

### 5.0 Sign off

**Privacy Officer Assessment**

Based on the information provided in this assessment, I agree with the privacy impact rating of Low. Accordingly, I consider:

 A full PIA is not required This is because [select as many as applicable]:

* Some personal information is involved, but the proposed controls mitigate the risks satisfactorily
* The project will lessen existing privacy risks, and includes satisfactory mitigations of any further risks

|  |  |  |
| --- | --- | --- |
| **Viv Kerr** |  | **Interim Privacy Officer**  |
| **Name** |  | **Position** |
| **V. Kerr** |  | **09 December 2022** |
| **Signature** |  | **Date** |

**5. Project Sign-off**

|  |  |  |
| --- | --- | --- |
| **Astrid Koornneef** |  | **Interim Director** |
| **Name** |  | **Position** |
| **A. Koornneef** |  | **12 December 2022** |
| **Signature** |  | **Date** |